Gufic Biosciences Limited's 42nd AGM: All resolutions passed, including dividend and director re-appointments.
Gufic Biosciences Limited's 42nd AGM on September 4, 2026, passed all resolutions. Key approvals include the FY26 financial statements, a 10% final dividend (Re. 0.10/share), director re-appointments for Mr. Pranav J. Choksi and Mr. Pankaj J. Gandhi, and auditor remuneration.
The passing of resolutions related to financial statements, dividend, and board appointments are routine for an AGM but are important for company operations and shareholder returns, thus having a medium impact.
All resolutions, including financial statement adoption, dividend declaration, and director re-appointments, were passed with overwhelming support, indicating positive shareholder confidence.
Gufic Biosciences Limited held its 42nd Annual General Meeting (AGM) on Friday, September 04, 2026, through Video Conferencing/Other Audio Visual Means. The meeting, which commenced at 03:30 PM and concluded at 04:09 PM, saw the successful passing of all five resolutions presented to the shareholders.
The resolutions passed included the adoption of the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026, along with the Board and Auditors' reports. Shareholders also approved the declaration of a Final Dividend of 10%, equivalent to Re. 0.10 per equity share of Re. 1/- face value, for the financial year ended March 31, 2026.
Furthermore, the AGM approved the re-appointment of Mr. Pranav J. Choksi as a director, who retired by rotation and offered himself for re-appointment. The shareholders also ratified the remuneration payable to M/s. Poddar & Co., Cost Auditors, for the Financial Year 2026-27. Lastly, the re-appointment of Mr. Pankaj J. Gandhi as Whole Time Director, continuing his directorship upon attaining the age of 70 years, was also approved as a special resolution.
The voting results, compiled from remote e-voting and e-voting during the AGM, indicated overwhelming support for all resolutions, with a very minimal percentage of votes cast against them. The consolidated scrutinizer's report, submitted on September 07, 2026, confirmed the passing of all ordinary and special resolutions with the requisite majority.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.